Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1

AIDS Research and Human Retroviruses

Volumn 15, Issue 6, 1999, Pages 523-531

  Hioe, Catarina E ^a   Hildreth, James E K ^b   Zolla Pazner, Susan ^a,c  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY;

ANTIBODY DETECTION; ANTIGENICITY; ARTICLE; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY; TARGET CELL; VIRUS CELL INTERACTION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; NEUTRALIZATION TESTS;

EID: 0033541477     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311042     Document Type: Article

References (39)

1. Bastiani L, Laal S, Kim M, and Zolla-Pazner S: Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol 1997;71:3444-3450.
2. Fais S, Capobianchi MR, Abbate I, Castilletti C, Gentile M, Fei PC, Ameglio F, and Dianzani F: Unidirectional budding of HIV-1 at the site of cell-to-cell contact is associated with co-polarization of intercellular adhesion molecules and HIV-1 viral matrix protein. AIDS 1995;9:329-335.
3. Frank I, Stoiber H, Godar S, Stockinger H, Steindl F, Katinger HW, and Dierich MP: Acquisition of host cell-surface-derived molecules by HIV-1. AIDS 1996;10:1611-1620.
4. Capobianchi MR, Fais S, Castilletti C, Gentile M, Ameglio F, and Dianzani F: A simple and reliable method to detect cell membrane proteins on infectious human immunodeficiency virus type 1 particles. J Infect Dis 1994;169:886-889.
5. Orentas RJ and Hildreth JE: Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Res Hum Retroviruses 1993;9:1157-1165.
6. Fortin JF, Cantin R, Lamontagne G, and Tremblay M: Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 1997;71:3588-3596.
7. Rizzuto CD and Sodroski JG: Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol 1997;71:4847-4851.
8. Fortin JF, Cantin R, and Tremblay MJ: T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1. J Virol 1998;72:2105-2112.
9. Hildreth JE and Orentas RJ: Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. Science 1989;244:1075-1078.
10. Butini L, De Fougerolles AR, Vaccarezza M, Graziosi C, Cohen DI, Montroni M, Springer TA, Pantaleo G, and Fauci AS: Intercellular adhesion molecules (ICAM)-1, ICAM-2 and ICAM-3 function as counter-receptors for lymphocyte function-associated molecule 1 in human immunodeficiency virus-mediated syncytia formation. Eur J Immunol 1994;24:2191-2195.
11. Gruber MF, Webb DS, Gerrard TL, Mostowski HS, Vujcic L, and Golding H: Re-evaluation of the involvement of the adhesion molecules ICAM-1/LFA-1 in syncytia formation of HIV-1-infected subclones of a CEM T-cell leukemic line. AIDS Res Hum Retroviruses 1991;7:45-53.
12. Berman PW and Nakamura GR: Adhesion mediated by intercellular adhesion molecule 1 attenuates the potency of antibodies that block HIV-1 gp160-dependent syncytium formation. AIDS Res Hum Retroviruses 1994;10:585-593.
13. Gomez MB and Hildreth JE: Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1. J Virol 1995;69:4628-4632.
14. Cecilia D, Kewalramani V, O'Leary J, Vosky B, Nyambi P, Burda S, Xu S, Littman D, and Zolla-Pazner S: Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol 1998;72:6988-6996.
15. Hioe CE, Xu S, Chigurupati P, Burda S, Williams C, Gorny MK, and Zolla-Pazner S: Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immunol 1997;9:1281-1290.
16. Hildreth JE and August JT: The human lymphocyte function-associated (HLFA) antigen and a related macrophage differentiation antigen (HMac-1): Functional effects of subunit-specific monoclonal antibodies. J Immunol 1985;134:3272-3280.
17. Sanchez-Madrid F, Krensky AM, Ware CF, Robbins E, Strominger JL, Burakoff SJ, and Springer TA: Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc Natl Acad Sci USA 1982;79:7489-7493.
18. Hildreth JE, Holt V, August JT, and Pescovitz MD: Monoclonal antibodies against porcine LFA-1: Species cross-reactivity and functional effects of beta-subunit-specific antibodies. Mol Immunol 1989;26:883-895.
19. Gorny MK, Xu JY, Karwowska S, Buchbinder A, and Zolla-Pazner S: Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 1993; 150: 635-643.
20. Conley AJ, Gorny MK, Kessler JA II, Boots LJ, Ossorio-Castro M, Koenig S, Lineberger DW, Emini EA, Williams C, and Zolla-Pazner S: Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 1994;68:6994-7000.
21. McKeating JA, Thali M, Furman C, Karwowska S, Gorny MK, Cordell J, Zolla-Pazner S, Sodroski J, and Weiss RA: Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virology 1992;190:134-142.
22. Zolla-Pazner S, O'Leary J, Burda S, Gorny MK, Kim M, Mascola J, and McCutchan F: Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J Virol 1995;69:3807-3815.
23. Barbas CF III, Hu D, Dunlop N, Sawyer L, Cababa D, Hendry RM, Nara PL, and Burton DR: In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci USA 1994;91:3809-3813.
24. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al.: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-1027.
25. Laal S, Burda S, Sharpe S, and Zolla-Pazner S: A rapid, automated microtiter assay for measuring neutralization of HIV-1. AIDS Res Hum Retroviruses 1993;9:781-785.
26. Wawryk SO, Novotny JR, Wicks IP, Wilkinson D, Maher D, Salvans E, Welch K, Fecondo J, and Boyd AW: The role of the LFA-1/ICAM-1 interaction in human leukocyte homing and adhesion. Immunol Rev 1989;108:135-161.
27. Dustin ML and Springer TA: T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature (London) 1989;341:619-624.
28. Dongworth DW, Gotch FM, Hildreth JE, Morris A, and McMichael AJ: Effects of monoclonal antibodies to the alpha and beta chains of the human lymphocyte function-associated (H-LFA-1) antigen on T lymphocyte functions. Eur J Immunol 1985;15:888-892.
29. Krensky AM, Robbins E, Springer TA, and Burakoff SJ: LFA-1, LFA-2, and LFA-3 antigens are involved in CTL-target conjugation. J Immunol 1984;132:2180-2182.
30. Zolla-Pazner S and Sharpe S: A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. AIDS Res Hum Retroviruses 1995;11:1449-1458.
31. Ugolini S, Mondor I, Parren PW, Burton DR, Tilley SA, Klasse PJ, and Sattentau QJ: Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med 1997;186:1287-1298.
32. Moore JP, Trkola A, and Dragic T: Co-receptors for HIV-1 entry. Curr Opin Immunol 1997;9:551-562. [See comments]
33. McInerney TL, McLain L, Armstrong SJ, and Dimmock NJ: A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizing by inhibiting a postfusion event. Virology 1997;233: 313-326.
34. Goudsmit J and Smit L: CD11a/CD18 (LFA-1) epitopes involved in syncytium formation among CD4+ T-cells following cell free HIV-1 infection. Virol Immunol 1990;3:289-293.
35. Busso M, Thornthwaite J, and Resnick L: HIV-induced syncytium formation requires the formation of conjugates between virus-infected and uninfected T-cells in vitro. AIDS 1991;5:1425-1432.
36. Tsunetsugu-Yokota Y, Yasuda S, Sugimoto A, Yagi T, Azuma M, Yagita H, Akagawa K, and Takemori T: Efficient virus transmission from dendritic cells to CD4+ T cells in response to antigen depends on close contact through adhesion molecules. Virology 1997;239:259-268.
37. Sawyer LS, Wrin MT, Crawford-Miksza L, Potts B, Wu Y, Weber PA, Alfonso RD, and Hanson CV: Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol 1994;68: 1342-1349.
38. Montefiori DC, Collman RG, Fouts TR, Zhou JY, Bilska M, Hoxie JA, Moore JP, and Bolognesi DP: Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J Virol 1998;72:1886-1893.
39. Zolla-Pazner S, Xu S, Burda S, Duliege A-M, Excler J-L, and Clements-Mann ML: Neutralization of syncytium-inducing primary isolates by sera from HIV-uninfected recipients of candidate HIV vaccines. J Infect Dis 1998;178:1502-1506.